Budget 2022: “Mention of Genomics & Pharma as sunrise opportunities is encouraging”

As the country moves towards good health and economic well-being, it is critical to continue to innovate in India and the rest of the world, says Sanjiv Navangul, Managing Director & CEO, Bharat Serums and Vaccines Limited

0
72
New Delhi: “We are encouraged by the recently announced roll out of the open National Digital Health Ecosystem platform that will further augment our country’s digital healthcare journey and create positive patient outcomes with digital registries of health providers and health facilities, unique health identity, consent framework and universal access to health facilities. As the country moves towards good health and economic well-being, it is critical to continue to innovate in India and the rest of the world,” says Sanjiv Navangul, Managing Director & CEO, Bharat Serums and Vaccines Limited.
Navangul adds: “Today, the booming biotech innovation across the globe along with the accelerated adoption of digital technologies has redefined the contours of healthcare management. To build and grow the research-driven biopharmaceutical industry in India we continue to seek an enabling, supportive regulatory and policy framework that encourages and promotes research in order to bring positive patient outcomes.”
“Further the Union Budget 2022 outlines ‘Genomics and Pharmaceuticals’ as the sunrise opportunities eligible for a supportive framework to build domestic capacities and promote Research & Development.  This is encouraging as we collectively work towards building an Aatmanirbhar Bharat and an ‘Amrit Kal’ for every citizen of the country,” concludes Navangul.